On 28 February 2024, Celltrion announced that its first batch of Zymfentra® (SC infliximab) arrived in Atlanta, with three more shipments expected to arrive by early March this year. Zymfentra® was approved by the FDA in October 2023.
Zymfentra® (SC infliximab), also known as Remsima SC in Europe, is the world’s first subcutaneous injection of infliximab. Zymfentra® can be self-administered increasing patient convivence and reducing hospital burden. Celltrion aims to distribute Zymfentra® to US wholesalers by mid-March.
Zymfentra® was approved by the FDA in October 2023.